**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 48307

**Manuscript Type:** MINIREVIEWS

**Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis using pancreatic stents: A review of efficacy, diameter and length**

Sugimoto M *et al*. Pancreatic stents for PEP: A review

Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Mika Takasumi, Minami Hashimoto, Takuto Hikichi, Hiromasa Ohira

**Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Mika Takasumi, Minami Hashimoto, Hiromasa Ohira,** Department of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima 9601247, Japan

**Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Minami Hashimoto, Takuto Hikichi,** Department of Endoscopy, Fukushima Medical University Hospital, Fukushima 9601295, Japan

**ORCID number:** Mitsuru Sugimoto (0000-0002-4223-613X); Tadayuki Takag (0000-0003-0696-5973); Rei Suzuki (0000-0002-4049-0484); Naoki Konno (0000-0001-9830-4317); Hiroyuki Asama (0000-0002-0102-0404); Yuki Sato (0000-0001-8000-0972); Hiroki Irie (0000-0002-4805-6244); Ko Watanabe (0000-0003-3895-7636); Jun Nakamura (0000-0001-6006-1778); Mika Takasumi (0000-0002-6025-8084); Minami Hashimoto ([0000-0002-5750-7182](https://orcid.org/0000-0002-5750-7182)); Takuto Hikichi (0000-0002-9815-1557); Hiromasa Ohira (0000-0003-4331-0634).

**Author contributions:** Sugimoto M designed and performed the study; Sugimoto M, Takag T, and Ohira H analyzed the data; Sugimoto M, Takag T, and Ohira H wrote the paper; Suzuki R, Konno N, Asama H, Hikichi T, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Sato Y, Hashimoto M, and Irie H provided clinical advice; and Hikichi T and Ohira H supervised the study.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Tadayuki Takagi, MD, PhD, Assistant Professor, Doctor,** Department of Gastroenterology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 9601247, Japan. daccho@fmu.ac.jp

**Telephone:** +81-24-5471202

**Fax:** +81-24-5472055

**Received:** April 15, 2019

**Peer-review started:** April 15, 2019

**First decision:** May 8, 2019

**Revised:** June 2, 2019

**Accepted:** June 10, 2019

**Article in press:**

**Published online:**

**Abstract**

Although endoscopic retrograde cholangiopancreatography (ERCP) is an important procedure for the diagnosis and treatment of pancreaticobiliary diseases, post-ERCP pancreatitis (PEP) is the most frequent adverse event that can sometimes be fatal. However, prophylactic pancreatic stent (PS) insertion has been performed to prevent PEP in high-risk patients. In some randomized controlled trials (RCTs) and meta-analyses, the efficacy of prophylactic PS insertion has been shown to prevent PEP. In addition, several types of stents have been used to decrease PEP. In this review, we introduce the details of these RCTs and meta-analyses and reveal the specifications for stent placement, for example, the stent diameter and length and the pancreatic region into which the stent should be inserted.

**Key words:** Endoscopic retrograde cholangiopancreatography; Post-endoscopic retrograde cholangiopancreatography pancreatitis; Prophylactic pancreatic stent

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most frequent adverse event that can sometimes be fatal. Pancreatic stent (PS) insertion is recommended to prevent PEP based on some randomized controlled trials (RCTs) and meta-analyses. Currently, several types of PS have been used. In this review, we introduce these RCTs and meta-analyses and reveal what stent should be used.

Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Hikichi T, Ohira H. Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis using pancreatic stents: A review of efficacy, diameter and length. *World J Meta-Anal* 2019; In press

**INTRODUCTION**

Endoscopic retrograde cholangiopancreatography (ERCP) is an important procedure for the diagnosis and treatment of pancreaticobiliary diseases but is sometimes a dangerous procedure. Several adverse events related to ERCP have been reported (duodenal perforation, bleeding, *etc*)[[1-4](#_ENREF_1)]. Among them, post-ERCP pancreatitis (PEP) is the most frequent adverse event and is sometimes fatal. According to past reports, PEP occurs in 0.4%-5.6% of patients[[5-12](#_ENREF_5)], and the mortality rate of PEP is 0-0.1%[[8](#_ENREF_8),[10-12](#_ENREF_10)]. The risk factors of PEP that have been specified in past reports were history of previous PEP, more than two contrast injections into the pancreatic duct, sphincter of Oddi dysfunction (SOD), age less than 50 years, female gender, difficult biliary duct cannulation, biliary sphincter balloon dilation, precut sphincterotomy, and a history of previous pancreatitis[[11-19](#_ENREF_11)]. As prophylaxis for PEP in high-risk patients with these risk factors, pancreatic stent (PS) insertion is a preventative option. In this review, we present our investigations on the efficacy of PS placement for preventing PEP, and we disclose what stent should be selected and how the PS should be inserted.

**SEARCH STRATEGY**

The studies included in this review were retrieved from PubMed using the following keywords: “Post-ERCP pancreatitis” and “pancreatic stent”. Furthermore, studies written in English were selected. Only randomized controlled trials (RCTs) and meta-analyses that examined the efficacy of PS for preventing PEP were selected for further analysis. Studies that compared different stents (flanged or unflanged, diameter, length) were analyzed to determine which PSs should be used.

**ADAPTATION OF PROPHYLACTIC PS INSERTION**

As mentioned above, patients with high risk factors become candidates for prophylactic PS insertion. The patients recommended PS insertion had a history of previous PEP, SOD, difficult biliary duct cannulation, biliary sphincter balloon dilation, precut sphincterotomy or sphincterotomy, pancreatic duct cannulation or contrast agent injection to the pancreatic duct, or endoscopic ampullectomy[[20](#_ENREF_20)].

**RCTs**

In an RCT in 1993, Smithline *et al*[[21](#_ENREF_21)] reported first prophylactic PS insertion for preventing PEP. In the report, the risk factors of PEP were acinarization, precutting, and a history of pancreatitis. The report could not prove the efficacy of PS insertion and did not recommend PS for PEP (PEP rate: stent group 14% (6/43) *vs* 18% (9/50),*P* = 0.299). However, several additional RCTs were performed, and the total number of RCTs on this topic increased to eleven from 1993 to 2016[[21-31](#_ENREF_21)] (Table 1). Except for the first report written by Smithline, all reports indicated the efficacy of PS insertion for preventing PEP, and severe PEP did not occur in patients who received a PS[[22-31](#_ENREF_22)]. Although a significant difference was not observed, the PEP rate was lower in the stent group than in the no stent group in the report written by Tsuchiya *et al*[25] [stent group 1/32 (3.1%) *vs* no stent group 4/32 (12.5%), *P* > 0.05].

**PS FOR AMPULLECTOMY**

In 2005, Harewood *et al*[[32](#_ENREF_32)] reported on prophylactic PS placement for endoscopic snare excision of the duodenal ampulla. In this study, 19 patients were enrolled, and 10 received a PS. Although the number of participants was small, postprocedure pancreatitis was significantly higher in patients without PS than in patients with PS [33% (3/9) *vs* 0% (0/10), *P* = 0.02].

**META-ANALYSES**

Among the eleven RCTs, PEP occurred more in patients without PS than in patients with PS. PS insertion was recommended for preventing PEP. Additionally, severe PEP did not occur in any patient who received a PS in all eleven RCTs. However, the frequency of severe PEP was not significantly different between the stent group and the no stent group in any of the RCTs. The results of severe PEP referred to the small sample size in each RCT and far fewer patients with severe PEP. These facts indicated that prophylactic PS might prevent not only total PEP but also severe PEP.

The usefulness of prophylactic PS placement for preventing severe PEP was not statistically recognized within each RCT. However, six meta-analyses were previously performed on prophylactic PS placement to prevent PEP[[33-38](#_ENREF_33)] (Table 2). Among them, two of the six meta-analyses reported that prophylactic PS insertion did not statistically prevent severe PEP[[33](#_ENREF_33),[35](#_ENREF_35)]. As more cases of prophylactic PS were reported, the second-most recent meta-analysis was conducted by Shi *et al*[[37](#_ENREF_37)]; however, the efficacy of prophylactic PS for preventing severe PEP could not be proven. As a cause, the meta-analysis involved only full text articles and excluded articles with only abstracts, and the number of cases became small. On the other hand, two meta-analyses written by Mazaki *et al*[[34](#_ENREF_34),[36](#_ENREF_36)] involved both full-text articles and articles with only abstracts; therefore, the number of cases was large. In the two meta-analyses written by Mazaki *et al*[[34](#_ENREF_34),[36](#_ENREF_36)], the efficacy of prophylactic PS insertion for preventing severe PEP was indicated (2010: stent group 0/336 *vs* no stent group 7/344, *P* < 0.04, 2014: stent group 0/694 *vs* no stent group 13/718, *P* = 0.01). Furthermore, in the most recent meta-analysis written by Fan *et al*[38], severe PEP was significantly lower in patients with a PS than in patients without a PS (stent group 0/493 *vs* no stent group 13/516, *P* < 0.01).

From a meta-analysis, it became apparent that prophylactic PS might be efficient for preventing not only PEP but also severe PEP.

**WHAT STENT SHOULD BE USED?**

As described above, PEP is reduced by PS insertion. However, several forms, diameters, and lengths of PSs exist. What stent should we use (Table 3)?

***Internal flanged or unflanged***

In 2018, He *et al*[39] compared 5-Fr 3 cm internal unflanged stents with a single pigtail on the duodenal side and 5-Fr 3 cm internal flanged stents with a single pigtail on the duodenal side. The PEP rates were not different between the two types of stents [unflanged stents 5.07% (7/138) *vs* flanged stents 7.97% (11/138), *P* = 0.329]. However, spontaneous PS displacement at 5 d was significantly higher in the internal unflanged stent group than in the internal flanged stent group [unflanged stent 47.72% (63/138) *vs* flanged stent 15.67% (21/134), *P* < 0.001]. Furthermore, spontaneous PS displacement at 14 d was significantly higher in the internal unflanged stent group than in the internal flanged stent group [unflanged stent 84.21% (112/133) *vs* flanged stent 42.65% (58/136), *P* < 0.001]. When the internal unflanged stent with a single pigtail on the duodenal side was used, an additional endoscope insertion to remove the PS was avoided.

***PS diameter***

In past reports, the diameter of the PS makes a difference not only in the occurrence of PEP but also in usability. In 2004, Rashdan *et al*[[40](#_ENREF_39)] wrote a retrospective study about prophylactic PS placement in 2940 cases. They described that small-diameter stents (*i.e.*, 3-4-Fr) were more effective than were 5-Fr or 6-Fr stents in preventing PEP [PEP rate: 3-4-Fr stent 8.7% (213/2447) *vs* 5-6-Fr stent 11.0 % (54/493), *P* = 0.0471]. However, Zolotarevsky *et al*[42] reported that there was no significant difference in the PEP rate between patients who received a 3-Fr PS and patients who received a 5-Fr PS. However, insertion of a 5-Fr stent was faster (9.2 min *vs* 11.1 min, *P* = 0.355), easier [mean modified 5-point Likert scale[[41](#_ENREF_40),42]: 1.8 (5-Fr) *vs* 3.4 (3-Fr), *P* < 0.01], and required fewer wires [1.5 (5-Fr) *vs* 1.9 (6-Fr), *P* = 0.002] than insertion of a 3-Fr PS[[43](#_ENREF_42)]. Pahk *et al*[[44](#_ENREF_43)] reported that spontaneous passage was more frequent with 4-Fr PSs than with 5-Fr PSs [95.8% (115/137) *vs* 68.7% (134/209), *P* < 0.001 (by log-rank test)]; therefore, the need for additional endoscopy to retrieve the PS was reduced by using a 4-Fr PS. However, the incidence of PEP was not significantly different between the 4-Fr PS group and the 5-Fr PS group. An additional report stated that insertion of a PS with a diameter > 5-Fr was effective in preventing PEP (PEP rate: > 5-Fr > 5 cm 1.4% *vs* ≤ 5-Fr ≤ 5 cm 9.4%, *P* = 0.0252)[[45](#_ENREF_44)].

Pahk Based on the above results, whether the diameter of PS influences the occurrence of PEP remains controversial. According to past reports, thin stents (*i.e.*, 3-Fr or 4-Fr) should be used with the expectation of spontaneous dislodgment, and a 5-Fr stent should be used in cases that were difficult to insert PS.

***PS length***

Few reports have described the length of PSs (Table 3). In 2009, Chahal *et al*[[46](#_ENREF_45)] compared the occurrence of PEP between 5-Fr, 3 cm long unflanged PSs and 3-Fr, 8 cm or longer unflanged PSs. PEP was less frequent in the 5-Fr, 3 cm stent group than in the 3-Fr, long-stent group [PEP rate: 3-Fr 8 cm 14% (18/133) *vs* 5-Fr 3 cm 9% (11/116), *P* = 0.30]. However, significant differences between these two groups were not observed. Fujisawa *et al*[[47](#_ENREF_46)] compared PS lengths (unflanged straight stent, 5-Fr at 3 cm *vs* 5-Fr at 5 cm) and reported that the PEP rate and the median time until stent dislodgement were both lower in the 3 cm group than in the 5 cm group (PEP rate: 3 cm 2.0% *vs* 5 cm 8.8%, *P* = 0.035, median period until spontaneous PS dislodgement: 3 cm 2 d *vs* 5 cm 4 d, *P* < 0.001). In this report, earlier stent dislodgement of the 3 cm PS might contribute to preventing PS obstruction-induced PEP. However, Olsson *et al*[[45](#_ENREF_44)] reported that a PS with a length > 5 cm and a diameter > 5 Fr is the most effective in preventing PEP. In this report, the frequency of PEP was not significantly different between patients who received a PS ≤ 5 cm and patients who received a PS > 5 cm.

These results regarding the influence of PS length on PEP varied, and we propose two explanations for these inconsistencies. Perhaps the diameters of PS were not matched, except for in the second report written by Fujisawa *et al*[[47](#_ENREF_46)]; although in this report the pancreatic region into which the PS was inserted was not investigated, and only PS length was investigated. Pancreas size differs among people; therefore, both a 3 cm and 5 cm stent can be inserted into the pancreatic head depending on the patient. However, spontaneous dislodgement could contribute to preventing PEP if both a 3 cm and 5 cm PS were inserted in or near to the pancreatic head.

***Location in the pancreas of PS insertion***

As described in the previous section, the PEP rate was compared between patients who received a PS ≤ 5 cm and patients who received a PS > 5 cm in a report written by Olsson *et al*[[45](#_ENREF_44)]. In comparison, the PEP rate was not significantly different between the two groups. In patients who received a PS > 5 cm, the stent might reach the pancreatic body or the tail. However, the pancreatic regions into which the stents were inserted were not described.

However, Sugimoto *et al*[[48](#_ENREF_47)] compared hyperamylasemia and the PEP rate between patients who had a PS inserted into the pancreatic head (the head group) and patients who had a PS inserted into the pancreatic body or tail (the body/tail group). Although a significant difference was not observed, the PEP rate was lower in the body/tail group than in the head group [0% (0/16) *vs* 9.2% (12/131), *P* = 0.363]; PEP was not observed in the body/tail group. Furthermore, after ERCP, the level of the pancreatic isozyme of serum amylase was significantly higher in the head group than in the body/tail group [138.5 (7.0-2086) IU/L *vs* 78.5 (5.0-1266.5) IU/L, *P* = 0.03]. Proteinase activation, which exacerbates pancreatitis, is induced by difficult pancreatic duct drainage[[49](#_ENREF_48)]; therefore, stent placement up to the pancreatic body or tail contributes to greater pancreatic drainage than stent placement in the pancreatic head does.

**CONCLUSION**

The results of several RCTs and meta-analyses have revealed that PS is efficient for preventing PEP. However, PEP can occur in patients who underwent stent placement. Currently, the main argument is which PS should be used. Additional endoscopic insertion to remove the PS could be avoided by using an internal unflanged PS. The diameter of PS is controversial because thin stents easily migrate, and thick stents are easily inserted in some cases. With respect to the length of the stent, a 3 cm stent may be more efficient than a 5 cm stent in preventing PEP. However, the risk of PEP may be altered according to the pancreatic region into which the PS is inserted.

Overall, there remain few cases in which a prophylactic PS was utilized; therefore, the accumulation of additional cases is necessary.

**REFERENCES**

1 **Bergman JJ**, Rauws EA, Fockens P, van Berkel AM, Bossuyt PM, Tijssen JG, Tytgat GN, Huibregtse K. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. *Lancet* 1997; **349**: 1124-1129 [PMID: 9113010 DOI: 10.1016/s0140-6736(96)11026-6]

2 **Howard TJ**, Tan T, Lehman GA, Sherman S, Madura JA, Fogel E, Swack ML, Kopecky KK. Classification and management of perforations complicating endoscopic sphincterotomy. *Surgery* 1999; **126**: 658-63; discussion 664-5 [PMID: 10520912 DOI: 10.1016/S0039-6060(99)70119-4]

3 **Stapfer M**, Selby RR, Stain SC, Katkhouda N, Parekh D, Jabbour N, Garry D. Management of duodenal perforation after endoscopic retrograde cholangiopancreatography and sphincterotomy. *Ann Surg* 2000; **232**: 191-198 [PMID: 10903596 DOI: 10.1097/00000658-200008000-00007]

4 **Baron TH**, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. *Am J Gastroenterol* 2004; **99**: 1455-1460 [PMID: 15307859 DOI: 10.1111/j.1572-0241.2004.30151.x]

5 **Reiertsen O**, Skjøtø J, Jacobsen CD, Rosseland AR. Complications of fiberoptic gastrointestinal endoscopy--five years' experience in a central hospital. *Endoscopy* 1987; **19**: 1-6 [PMID: 3493897 DOI: 10.1055/s-2007-1013011]

6 **Sherman S**, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, Silverman WB, Earle DT, Lehman GA. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. *Gastrointest Endosc* 1994; **40**: 422-427 [PMID: 7926531 DOI: 10.1016/S0016-5107(94)70204-7]

7 **Johnson GK**, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, Hogan WJ, Ryan M, Silverman W, Edmundowicz S. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary Study Group. *Gastrointest Endosc* 1995; **42**: 312-316 [PMID: 8536898 DOI: 10.1016/S0016-5107(95)70128-1]

8 **Freeman ML**, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. *N Engl J Med* 1996; **335**: 909-918 [PMID: 8782497 DOI: 10.1056/nejm199609263351301]

9 **Loperfido S**, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointest Endosc* 1998; **48**: 1-10 [PMID: 9684657 DOI: 10.1016/S0016-5107(98)70121-X]

10 **Andriulli A**, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol* 2007; **102**: 1781-1788 [PMID: 17509029 DOI: 10.1111/j.1572-0241.2007.01279.x]

11 **Glomsaker T**, Hoff G, Kvaløy JT, Søreide K, Aabakken L, Søreide JA; Norwegian Gastronet ERCP Group. Patterns and predictive factors of complications after endoscopic retrograde cholangiopancreatography. *Br J Surg* 2013; **100**: 373-380 [PMID: 23225493 DOI: 10.1002/bjs.8992]

12 **Katsinelos P**, Lazaraki G, Chatzimavroudis G, Gkagkalis S, Vasiliadis I, Papaeuthimiou A, Terzoudis S, Pilpilidis I, Zavos C, Kountouras J. Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. *Ann Gastroenterol* 2014; **27**: 65-72 [PMID: 24714755 DOI: 10.1097/SLE.0000000000000012]

13 **Chen JJ**, Wang XM, Liu XQ, Li W, Dong M, Suo ZW, Ding P, Li Y. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. *Eur J Med Res* 2014; **19**: 26 [PMID: 24886445 DOI: 10.1186/2047-783X-19-26]

14 **Cotton PB**, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointest Endosc* 2009; **70**: 80-88 [PMID: 19286178 DOI: 10.1016/j.gie.2008.10.039]

15 **Leghari A**, Ghazanfar S, Qureshi S, Taj MA, Niaz SK, Quraishy MS. Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centre. *J Coll Physicians Surg Pak* 2013; **23**: 620-624 [PMID: 24034184]

16 **Liu Y**, Su P, Lin S, Xiao K, Chen P, An S, Zhi F, Bai Y. Endoscopic papillary balloon dilatation versus endoscopic sphincterotomy in the treatment for choledocholithiasis: a meta-analysis. *J Gastroenterol Hepatol* 2012; **27**: 464-471 [PMID: 21913984 DOI: 10.1111/j.1440-1746.2011.06912.x]

17 **Masci E**, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. *Endoscopy* 2003; **35**: 830-834 [PMID: 14551860 DOI: 10.1055/s-2003-42614]

18 **Weinberg BM**, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. *Cochrane Database Syst Rev* 2006; CD004890 [PMID: 17054222 DOI: 10.1002/14651858.CD004890.pub2]

19 **Zhao HC**, He L, Zhou DC, Geng XP, Pan FM. Meta-analysis comparison of endoscopic papillary balloon dilatation and endoscopic sphincteropapillotomy. *World J Gastroenterol* 2013; **19**: 3883-3891 [PMID: 23840129 DOI: 10.3748/wjg.v19.i24.3883]

20 **Freeman ML**. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. *Clin Gastroenterol Hepatol* 2007; **5**: 1354-1365 [PMID: 17981248 DOI: 10.1016/j.cgh.2007.09.007]

21 **Smithline A**, Silverman W, Rogers D, Nisi R, Wiersema M, Jamidar P, Hawes R, Lehman G. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. *Gastrointest Endosc* 1993; **39**: 652-657 [PMID: 8224687 DOI: 10.1016/S0016-5107(93)70217-5]

22 **Tarnasky PR**, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. *Gastroenterology* 1998; **115**: 1518-1524 [PMID: 9834280 DOI: 10.1016/S0016-5085(98)70031-9]

23 **Fazel A**, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. *Gastrointest Endosc* 2003; **57**: 291-294 [PMID: 12612504 DOI: 10.1067/mge.2003.124]

24 **Sofuni A**, Maguchi H, Itoi T, Katanuma A, Hisai H, Niido T, Toyota M, Fujii T, Harada Y, Takada T. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. *Clin Gastroenterol Hepatol* 2007; **5**: 1339-1346 [PMID: 17981247 DOI: 10.1016/j.cgh.2007.07.008]

25 **Tsuchiya T**, Itoi T, Sofuni A, Itokawa F, Kurihara T, Ishii K, Tsuji S, Kawai T, Moriyasu F. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: a preliminary, single-center, randomized controlled trial. *J Hepatobiliary Pancreat Surg* 2007; **14**: 302-307 [PMID: 17520207 DOI: 10.1007/s00534-006-1147-8]

26 **Ito K**, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, Takasawa O, Koshita S, Kanno Y, Ogawa T. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic duct guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. *J Gastroenterol* 2010; **45**: 1183-1191 [PMID: 20607310 DOI: 10.1007/s00535-010-0268-7]

27 **Pan XP**, Dang T, Meng XM, Xue KC, Chang ZH, Zhang YP. Clinical study on the prevention of post-ERCP pancreatitis by pancreatic duct stenting. *Cell Biochem Biophys* 2011; **61**: 473-479 [PMID: 21739262 DOI: 10.1007/s12013-011-9230-4]

28 **Sofuni A**, Maguchi H, Mukai T, Kawakami H, Irisawa A, Kubota K, Okaniwa S, Kikuyama M, Kutsumi H, Hanada K, Ueki T, Itoi T. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. *Clin Gastroenterol Hepatol* 2011; **9**: 851-8; quiz e110 [PMID: 21749851 DOI: 10.1016/j.cgh.2011.06.033]

29 **Kawaguchi Y**, Ogawa M, Omata F, Ito H, Shimosegawa T, Mine T. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography. *World J Gastroenterol* 2012; **18**: 1635-1641 [PMID: 22529693 DOI: 10.3748/wjg.v18.i14.1635]

30 **Lee TH**, Moon JH, Choi HJ, Han SH, Cheon YK, Cho YD, Park SH, Kim SJ. Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. *Gastrointest Endosc* 2012; **76**: 578-585 [PMID: 22771100 DOI: 10.1016/j.gie.2012.05.001]

31 **Yin HK**, Wu HE, Li QX, Wang W, Ou WL, Xia HH. Pancreatic Stenting Reduces Post-ERCP Pancreatitis and Biliary Sepsis in High-Risk Patients: A Randomized, Controlled Study. *Gastroenterol Res Pract* 2016; **2016**: 9687052 [PMID: 27057161 DOI: 10.1155/2016/9687052]

32 **Harewood GC**, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. *Gastrointest Endosc* 2005; **62**: 367-370 [PMID: 16111953 DOI: 10.1016/j.gie.2005.04.020]

33 **Singh P**, Das A, Isenberg G, Wong RC, Sivak MV Jr, Agrawal D, Chak A. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. *Gastrointest Endosc* 2004; **60**: 544-550 [PMID: 15472676 DOI: 10.1016/S0016-5107(04)02013-9]

34 **Mazaki T**, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. *Endoscopy* 2010; **42**: 842-853 [PMID: 20886403 DOI: 10.1055/s-0030-1255781]

35 **Choudhary A**, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. *Gastrointest Endosc* 2011; **73**: 275-282 [PMID: 21295641 DOI: 10.1016/j.gie.2010.10.039]

36 **Mazaki T**, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. *J Gastroenterol* 2014; **49**: 343-355 [PMID: 23612857 DOI: 10.1007/s00535-013-0806-1]

37 **Shi QQ**, Ning XY, Zhan LL, Tang GD, Lv XP. Placement of prophylactic pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a meta-analysis. *World J Gastroenterol* 2014; **20**: 7040-7048 [PMID: 24944500 DOI: 10.3748/wjg.v20.i22.7040]

38 **Fan JH**, Qian JB, Wang YM, Shi RH, Zhao CJ. Updated meta-analysis of pancreatic stent placement in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. *World J Gastroenterol* 2015; **21**: 7577-7583 [PMID: 26140006 DOI: 10.3748/wjg.v21.i24.7577]

39 **He** **Q**, Wang L, Peng C, Zou X, Zhan Q, Xu Y, Liu Q, Qian J, Gong L, Shen Y, Chen J. Modified prophylactic 5-fr pancreatic duct stent enhances the rate of spontaneous dislodgement: A multicenter randomized controlled trial. *United European Gastroenterol J* 2018; **6**: 1519-1526 [PMID: 30574322 DOI: 10.1177/2050640618804729]

40 **Rashdan A**, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. *Clin Gastroenterol Hepatol* 2004; **2**: 322-329 [PMID: 15067627 DOI: 10.1016/S1542-3565(04)00062-X]

41 **Komorita SS**. Attitude Content, Intensity, And The Neutral Point On A Likert Scale. *J Soc Psychol* 1963; **61**: 327-334 [PMID: 14084811 DOI: 10.1080/00224545.1963.9919489]

42 **Likert R**. A technique for the measurement of attitudes. *Archives of psychology* 1932; **140**: 5-55

43 **Zolotarevsky E**, Fehmi SM, Anderson MA, Schoenfeld PS, Elmunzer BJ, Kwon RS, Piraka CR, Wamsteker EJ, Scheiman JM, Korsnes SJ, Normolle DP, Kim HM, Elta GH. Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. *Endoscopy* 2011; **43**: 325-330 [PMID: 21455872 DOI: 10.1055/s-0030-1256305]

44 **Pahk A**, Rigaux J, Poreddy V, Smith J, Al-Kawas F. Prophylactic pancreatic stents: does size matter? A comparison of 4-Fr and 5-Fr stents in reference to post-ERCP pancreatitis and migration rate. *Dig Dis Sci* 2011; **56**: 3058-3064 [PMID: 21487771 DOI: 10.1007/s10620-011-1695-x]

45 **Olsson G**, Lübbe J, Arnelo U, Jonas E, Törnqvist B, Lundell L, Enochsson L. The impact of prophylactic pancreatic stenting on post-ERCP pancreatitis: A nationwide, register-based study. *United European Gastroenterol J* 2017; **5**: 111-118 [PMID: 28405329 DOI: 10.1177/2050640616645434]

46 **Chahal P**, Tarnasky PR, Petersen BT, Topazian MD, Levy MJ, Gostout CJ, Baron TH. Short 5Fr vs long 3Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. *Clin Gastroenterol Hepatol* 2009; **7**: 834-839 [PMID: 19447196 DOI: 10.1016/j.cgh.2009.05.002]

47 **Fujisawa T**, Kagawa K, Ochiai K, Hisatomi K, Kubota K, Sato H, Nakajima A, Matsuhashi N. Prophylactic Efficacy of 3- or 5-cm Pancreatic Stents for Preventing Post-ERCP Pancreatitis: A Prospective, Randomized Trial. *J Clin Gastroenterol* 2016; **50**: e30-e34 [PMID: 26280707 DOI: 10.1097/MCG.0000000000000397]

48 **Sugimoto M**, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Hikichi T, Ohira H. Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail. *World J Gastroenterol* 2018; **24**: 2392-2399 [PMID: 29904246 DOI: 10.3748/wjg.v24.i22.2392]

49 **Kingsnorth A**. Role of cytokines and their inhibitors in acute pancreatitis. *Gut* 1997; **40**: 1-4 [PMID: 9155566 DOI: 10.1136/gut.40.1.1]

**P-Reviewer:** Isik A, Barret M **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**Table 1 Randomized controlled trials of prophylactic pancreatic stent insertion for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Yr** | **Country** | **Sample number** | **Risk factors** | **PEP *n* (%)**  | **Criteria for PEP** |
| **Stent** | **No stent** | **Stent/no stent** |
| Smithline *et al*[21] | 1993 | United States | 43 | 50 | Acinarization, pre-cutting, history of pancreatitis | Total 6 (14)/9 (18), *P* = 0.299; Mild 5 (12)/5 (10), *P* = NA; Moderate 1 (2)/2 (4) *P* = NA; Severe 0 (0)/2 (4), *P* = 0.264 | Cotton |
| Tarnasky *et al*[22] | 1998 | United States | 41 | 39 | SOD | Total 1 (2)/10 (26), *P* = 0.003; Mild 0 (0)/5 (13), *P* = NA; Moderate 0 (0)/5 (13), *P* = NA; Severe 0 (0)/0 (0), *P* = NA | Cotton |
| Fazel *et al*[23] | 2003 | United States | 38 | 36 | Difficult cannulationSOD | Total 2 (5.3)/10 (28), *P* < 0.05; Mild 2 (5.3)/5 (14), *P* = NA; Moderate 0 (0)/2(6), *P* = NA; Severe 0 (0)/3 (8), *P* = NA | Cotton |
| Sofuni *et al*[24] | 2007 | Japan | 98 | 103 | IDUS, biopsy, EPBD, SOD, POCS, Duodenal diverticulum, acinarization, initial pancreatography, difficulty of cannulation | Total 3 (3)/14 (13.6), *P* = 0.019; Mild 2 (2)/8 (7.8), *P* = 0.139; Moderate 1 (1)/6 (4.6), *P* = 0.156; Severe 0 (0)/0(0), *P* = NA | Cotton |
| Tsuchiya *et al*[25] | 2007 | Japan | 32 | 32 | EST, IDUS, EPBD, SOD, pancreatic duct cannulation | Total 1 (3.1)/4 (12.5), *P* > 0.05; Mild 1 (3.1)/2 (6.3), *P* = NA; Moderate 0 (0)/1 (3.1), *P* = NA; Severe 0 (0)/1 (3.1), *P* = NA | Cotton |
| Ito *et al*[26] | 2010 | Japan | 35 | 35 | History of pancreatitis, history of PEP, pancreatic duct opacification, EST, IDUS, EPBD, cytology of pancreatic juice, biopsy of pancreatic duct | Total 1 (2.9)/8 (23)(per-protocol) 0 (0)/9 (24), *P* = 0.0096; Mild 1 (2.9)/8 (23); Moderate and severe 0 | Cotton |
| Sofuni *et al*[28] | 2011 | Japan | 213 | 213 | History of pancreatitis, SOD, pancreatography, EST, precut sphincterotomy, EPBD, CBD tissue sampling, pancreatic duct tissue sampling, biliary drainage without EST, ENBD without EST, IDUS, difficulty of cannulation, long procedural time | (Intention to treat) Total 20 (9.4)/31 (14.6), *P* = 0.076; Mild 16 (7.5)/22 (10.3), *P* = 0.24; Moderate 4 (1.9)/8 (3.8), *P* = 389; Severe 0 (0)/1 (0.5), *P* = 1.00; (Full analysis set) Total 16 (7.9)/31 (15.2), *P* = 0.021; Moderate 12 (5.9)/22 (10.8), *P* = 0.77; Mild 4 (1.97)/8 (3.92), *P* = 0.952; Severe 0 (0)/1 (0.5), *P* = 1.00 | Cotton |
| Pan *et al*[27] | 2011 | China | 20 | 20 | History of pancreatitis, pancreatic duct cannulation, pancreatography, difficult cannulation, hyperamylasemia | Total 4 (20)/14 (70), *P* < 0.01; Mild, moderate, severe NA | Cotton |
| Kawaguchi *et al*[29] | 2012 | Japan | 60 | 60 | History of PEP, SOD, difficult cannulation, pre-cutting, pancreatic duct biopsy, IDUS of pancreatic duct | Total 1 (1.7)/8 (13.3), *P* = 0.032; Mild 1 (1.7)/8 (13.3), *P* = 0.032 | Modified Cotton |
| Lee *et al*[30] | 2012 | Korea | 50 | 51 | Difficult biliary cannulation, pancreatic cannulation | Total 6 (12)/15 (29.4), *P* = 0.031; Mild 5 (10)/12 (23.5), *P* = NA; Moderate 1 (2)/2 (3.9), *P* = NA; Severe 0 (0)/1 (2), *P* = NA | Cotton |
| Yin *et al*[31] | 2016 | China | 104 | 102 | History of PEP, cannulation difficulty, periampullary diverticulum | Total 8 (7.7)/18 (17.7), *P* = 0.031, Mild, Moderate, severe NA | NA |

RCT: Randomized controlled trial; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis; SOD: Sphincter of Oddi dysfunction; IDUS: Intraductal ultrasonography; EPBD: Endoscopic papillary balloon dilation; POCS: Peroral cholangioscopy; EST: Endoscopic sphincterotomy; CBD: Common bile duct; ENBD: Endoscopic nasobiliary drainage; NA: Not available.

**Table 2** **Meta-analyses of prophylactic pancreatic stent insertion for preventing Post-endoscopic retrograde cholangiopancreatography pancreatitis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author** | **Yr** | **Number of included studies** | **Type of included studies** | **PEP rate****Stent/no stent** | **PS insertion for preventing PEP** |
| Singh *et al*[33] | 2004 | 5 | Full text  | *n* = 206/275 | Recommended |
| Abstract | Total 12/43, *P* = 0.001Mild to moderate 12/36, *P* = 0.001; Severe 0/7, *P* = 0.15 |
| Mazaki *et al*[34] | 2010 | 8 | Full text | *n* = 336/344 | Recommended |
| Abstract | Total 19/64, *P* < 0.001; Mild to moderate 19/55, *P* < 0.001; Severe 0/7, *P* < 0.04 |
| Choudhary *et al*[35] | 2011 | 8 | Full text | *n* = 322/334 | Recommended |
| Abstract | Total 16/66, *P* < 0.00001 |
| Mazaki *et al*[36] | 2014 | 14 | Full text | *n* = 751/781 | Recommended |
| Abstract | Total 49/133, *P* < 0.001; Mild to moderate 49/120, *P* < 0.001; Severe 0/13, *P* = 0.01 |
| Shi *et al*[37] | 2014 | 10 | Full text | *n* = 561/584; Total 34/117, *P* < 0.001; Mild 24/70, *P* < 0.001; Moderate 6/24, *P* = 0.004; Severe 0/6, *P* = 0.077 | Recommended |
| Fan *et al*[38] | 2015 | 15 | Full text | *n* = 1233/1277 | Recommended |
| Abstract | Total 49/133, *P* < 0.00001; Mild 49/120, *P* < 0.00001; Severe 0/13, *P* < 0.00001 |

PS: Pancreatic stent; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.

**Table 3 Comparison of stent type**

|  |  |  |  |
| --- | --- | --- | --- |
| **Author, yr** | **Stent type** | ***n*** | **Results** |
| Flanged or unflanged |
| He *et al*[39], 2018 | Internal unflanged 5-Fr 3 cm stent with a single pigtail on the duodenal side *vs* internal flanged 5-Fr 3 cm stent with a single pigtail on the duodenal side | 138/138 | Spontaneous migration was more frequent with the internal unflanged stent (migration at five days: 47.72% *vs* 15.67%, *P* < 0.001, migration at 14 d 84.21% *vs* 42.65%, *P* < 0.001). |
| Comparison of stent diameter |
| Rashdan *et al*[40], 2004 | 3-4-Fr, 3-8 cm without internal flange *vs* 5-6-Fr, NA, with internal flange | 2447/493 | The 3-4-Fr stent was more effective in preventing PEP than the 5-6-Fr stent (PEP rate: 3-4-Fr stent 8.7% (213/2447) *vs* 5-6Fr 11.0 % (54/493), *P* = 0.0471). |
| Zolotarevsky *et al*[43], 2011 | 5-Fr 5 cm vs 3-Fr 6 cm | 38/40 | PEP rates did not differ. 5-Fr PS placement was easier [mean modified 5-point Likert scale[[40](#_ENREF_40),[41](#_ENREF_41)]: 1.8 (5-Fr) *vs* 3.4 (3-Fr), *P* < 0.01)], faster [9.2 (5-Fr) *vs* 11.1 minutes (3-Fr), *P* = 0.355], and required fewer wires [1.5 (5-Fr) *vs* 1.9 (6-Fr), *P* = 0.002]. |
| Pahk *et al*[44], 2011 | 4-Fr *vs* 5-Fr, both stents were 2 to 11 cm, unflanged | 137/209 | PEP rates did not differ. Spontaneous migration was more frequent with the 4-Fr stent [95.8% (115/137) *vs* 68.7% (134/209), *P* < 0.001 (by log-rank test)]. |
| Olsson *et al*[45], 2016 | ≤ 5-Fr, ≤ 5 cm *vs* > 5-Fr, > 5 cm | 241 (≤ 5-Fr)/135 (> 5-Fr) | The > 5-Fr, > 5 cm stent was more effective in preventing PEP (> 5-Fr, > 5 cm 1.4% *vs* ≤ 5-Fr, ≤ 5 cm 9.4%, *P* = 0.0252). |
| Comparison of stent length |
|  Chahal *et al*[46], 2009 | 5-Fr 3 cm, unflanged *vs* 3-Fr 8 cm or longer, unflanged | 116/133 | Spontaneous migration was more frequent with the 5-Fr 3 cm stent (5-Fr 98% *vs* 3-Fr 88%, *P* = 0.0001). Failure of PS placement was observed more often in the longer 3-Fr stent group (5-Fr 0/116 *vs* 3-Fr 11/133, *P* = 0.0003). PEP rates did not differ. |
|  Fujisawa *et al*[47], 2016 | 5-Fr 3 cm *vs* 5-Fr 5 cm, both stents were unflanged and straight | 98/102 | The 5-Fr 3 cm stent was more efficient for preventing PEP (3 cm 2.0% *vs* 5 cm 8.8%, *P* = 0.035). The period until spontaneous dislodgement was significantly shorter for the 3 cm stent than for the 5 cm stent (3 cm 2 d *vs* 5 cm 4 d, *P* < 0.001). |
| Part of the pancreas in which the stent was inserted |
|  Sugimoto *et al*[48], 2018 | Pancreatic head *vs* pancreatic body or tail  | 131/16 | After ERCP, the level of the pancreatic isozyme of serum amylase was higher in the head group than in the body/tail group [head group 138.5 (7.0-2086) IU/L *vs* body/tail group 78.5 (5.0-1266.5) IU/L, *P* < 0.03]. |

ERCP: Endoscopic retrograde cholangiopancreatography; PEP: Post-ERCP pancreatitis.